Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2
The experimentally established mechanism targets of Cytidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.90 |
| ▸ | MTOR | P42345 | 2/20 | 0.90 |
| ▸ | THRB | P10828 | 1/20 | 0.90 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.90 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.90 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | GMNN | O75496 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.59 |
| ▸ | THPO | P40225 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | HBB | P68871 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.59 |
| ▸ | NT5E | P21589 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytidine SCHEMBL1201153 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL376514 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL28898416 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL458337 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL9007590 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL285195 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL104628 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL6672407 | 0.99 | LMNA (0.88) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL29084328 | 0.99 | LMNA (0.88) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL2370482 | 0.99 | LMNA (0.88) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101705270-A | Method for synthesizing deoxycytidine triphosphate through biotechnology | JIANGSU HUARONG BIOLOG TECHNOL | 2010-05-12 | — | — | CN | claimed |
| WO-2025059367-A1 | TREX-1 AUGMENTATION TO ATTENUATE GENOTOXIC STRESS AND EXERT CARDIOPROTECTION | CEDARS-SINAI MEDICAL CENTER (US) | 2025-03-20 | — | — | WO | disclosed |
| US-12037579-B2 | Synthetic RNA binding polypeptides | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2023154848-A1 | COMPOSITIONS AND METHODS FOR MODULATING NUCLEAR ENRICHED ABUNDANT TRANSCRIPT 1 TO TREAT COGNITIVE IMPAIRMENT | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-4139043-A1 | METHODS FOR DIRECT SEQUENCING OF RNA | New York Institute of Technology (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20220220552-A1 | METHODS FOR DIRECT SEQUENCING OF RNA | NEW YORK INSTITUTE OF TECHNOLOGY | 2022-07-14 | — | — | US | disclosed |
| WO-2021216593-A1 | METHODS FOR DIRECT SEQUENCING OF RNA | NEW YORK INSTITUTE OF TECHNOLOGY (US) | 2021-10-28 | — | — | WO | disclosed |
| US-20210254042-A1 | METHODS AND COMPOSITIONS FOR SYNTHETIC RNA ENDONUCLEASES | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2021-08-19 | — | — | US | disclosed |
| US-20210198734-A1 | DIRECT NUCLEIC ACID SEQUENCING METHOD | NEW YORK INSTITUTE OF TECHNOLOGY | 2021-07-01 | — | — | US | disclosed |
| EP-3802821-A1 | DIRECT NUCLEIC ACID SEQUENCING METHOD | New York Institute of Technology (US) | 2021-04-14 | — | — | EP | disclosed |
| CN-101705270-A | Method for synthesizing deoxycytidine triphosphate through biotechnology | JIANGSU HUARONG BIOLOG TECHNOL | 2010-05-12 | — | — | CN | disclosed |
| CN-101356288-A | Methods using pores | ISIS INNOVATION (GB) | 2009-01-28 | — | — | CN | disclosed |
| CN-100413850-C | Chemical compounds | GLAXO GROUP LTD (GB) | 2008-08-27 | — | — | CN | disclosed |
| EP-1121455-A4 | ZINC FINGER PEPTIDE CLEAVAGE OF NUCLEIC ACIDS | ISIS PHARMACEUTICALS INC (US) | 2004-03-24 | — | — | EP | disclosed |
| CN-1391564-A | Chemical compounds | GLAXO GROUP LTD (GB) | 2003-01-15 | — | — | CN | disclosed |
| US-6365379-B1 | SELECTIVELY CLEAVING SINGLE STRANDED RNA BY CONTACTING WITH DIMERIZED ZINC FINGER PEPTIDE OF DEFINED AMINO ACID SEQUENCE IN ABSENSE OF ZINC | ISIS PHARMACEUTICALS, INC. | 2002-04-02 | — | — | US | disclosed |
| EP-1121455-A1 | ZINC FINGER PEPTIDE CLEAVAGE OF NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. (US) | 2001-08-08 | — | — | EP | disclosed |
| WO-2000020622-A9 | ZINC FINGER PEPTIDE CLEAVAGE OF NUCLEIC ACIDS | ISIS PHARMACEUTICALS INC (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000020622-A1 | ZINC FINGER PEPTIDE CLEAVAGE OF NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. (US) | 2000-04-13 | — | — | WO | disclosed |
| WO-1995032283-A1 | SEQUENCE-SPECIFIC ENDONUCLEASES, AND PREPARATION AND USE OF SAME | INDIANA UNIVERSITY FOUNDATION (US) | 1995-11-30 | — | — | WO | disclosed |